David Hallal, Scholar Rock CEO, joins 'Fast Money' to talk its recent drug study results that found its drug taken in ...

The U of A Honors College has selected 100 exceptional high school students, 91 of whom are from Arkansas, to receive Honors College Fellowships.

Scholar Rock's Apitegromab excels in Phase 2 trials, aiding muscle preservation with Tirzepatide. Click here to read why I ...

FLAT ROCK, MI — Flat Rock Community Schools announced the top 10 graduates in the Flat Rock High School Class of 2025. The ...

We recently published a list of These 10 Stocks Boast Double-Digit Gains Amid Boring Market. Scholar Rock Holding Corporation ...

Shares of Scholar Rock Holding (NASDAQ: SRRK) are soaring today, up 13.7% as of 1:14 p.m. ET. The move comes as the S&P 500 ...

Scholar Rock (NASDAQ: SRRK) has reported positive results from the phase 2 Embraze trial, demonstrating statistically ...

Shares of Scholar Rock Holdings jumped Wednesday after the biopharmaceutical firm reported positive results from a ...

“Scholar Rock is at an inflection point as we evolve to a commercial-stage biopharmaceutical company, and our team remains focused on key priorities in preparation for the potential U.S. launch ...

Scholar Rock's C-suite now looks radically different, as the company brought in a clutch of new top managers. The incoming CEO is David Hallal, the chairman of the company's board.

Pundit Allison Bratzel is quite bullish on its leading drug candidate. Scholar Rock targets relatively uncommon disorders that might lack effective treatments. Its current lead drug candidate ...

About Scholar Rock Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need.